IgA nephrosis (IgAN) treatment scheme comprehensive evaluating device

Abstract

The invention relates to the technical field of medical apparatuses, and specifically relates to an IgA nephrosis (IgAN) treatment scheme comprehensive evaluating device. The device comprises a machine body, a display screen, a menu button, adjustment buttons, a sample collection control button, a collecting groove, a collecting suction pipe, a power supply connector, a detection instrument, and a software operation management system. The front side of the machine body is provided with the display screen. The menu button is arranged under the display screen. The adjustment buttons are arranged in a circle array around the menu button, wherein the center of the menu button is taken as the circle center. The left side of the menu button is provided with the sample collection control button. The back of the machine body is provided with the collecting groove. The center of the collecting groove is provided with the collecting suction pipe. The power supply connector is arranged on the bottom of the machine body. The provided device is used to comprehensively evaluate the IgAN treatment scheme. The provided device is developed on the basis of clinical indexes (protein urine and kidney function) of IgAN patients, pathological score integration, and conventional medical evidences, and at the same time the clinical type and pathological characteristics are taken into account comprehensively. The provided device can comprehensively, nondestructively and quickly evaluate the clinical treatment scheme for IgAN patients and provides scientific and reasonable comprehensive treatment evaluation for doctors and IgAN patients.

Description

technical field [0001] The invention relates to the technical field of medical devices, in particular to a comprehensive evaluation device for IgA nephropathy (IgAN) treatment plan. Background technique [0002] IgAN refers to primary glomerular diseases such as IgA or IgA deposition in the glomerular mesangium, and is the most common cause of glomerular hematuria. It is currently the most common primary glomerular disease worldwide, accounting for about 10% to 40% of all renal biopsy cases and 20% to 50% of primary glomerular diseases. It is the highest in Asia, accounting for 30% to 40% of renal biopsy cases. It is also the most common glomerular disease in my country. The number of patients is large, the distribution is wide, and the heterogeneity is strong. It has become one of the main causes of end-stage renal disease. [0003] IgAN is common in young and middle-aged people, and the clinical manifestations vary in severity, and the treatment options and prognosis are ...

AI Technical Summary

Problems solved by technology

The pathological grading of IgAN has developed from a single grading to a semi-quantitative grading. The diversity of pathological classification includes the initial WHO grading, Lee's grading, and later Haas grading, mainly based on the severity of glomerular lesions and tubulointerstitial lesions. However, if it is used to guide clinical treatment, there are still many limitations

The Oxford IgAN classification, published in 2009, focuses on mesangial cell proliferation (M), intracapillary cell proliferation (E), segmental glomerulosclerosis (S), and tubular atrophy / interstitial fibrosis (T). Although the pathological quantitative scoring method of IgAN is given, it does not take into account tubulointerstitial inflammation, edema, and pathological manifestations of rapidly progressive nephropathy (such as crescents), so it cannot completely guide clinical

[0007] At present, the determination of proteinuria in patients with IgAN in hospitals is completed in the laboratory or laboratory, and it takes a certain amount of time to transmit the data to clinicians, which cannot be real-time, fast and convenient.

Images